| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Aditya Krishnan, Juliana Chizo Agwu, Chetana Kallappa, Rajesh Pande. Development of central precocious puberty following cannabinoid use for paediatric epilepsy: causal or coincidence? BMJ case reports. vol 14. issue 4. 2021-05-14. PMID:33858879. |
his mother procured cannabidiol oil online, which he started taking 7 months earlier for severe epilepsy refractory to medical management. |
2021-05-14 |
2023-08-13 |
monkey |
| Randi von Wrede, Christoph Helmstaedter, Rainer Surge. Cannabidiol in the Treatment of Epilepsy. Clinical drug investigation. vol 41. issue 3. 2021-05-04. PMID:33559102. |
cannabidiol in the treatment of epilepsy. |
2021-05-04 |
2023-08-13 |
Not clear |
| Randi von Wrede, Christoph Helmstaedter, Rainer Surge. Cannabidiol in the Treatment of Epilepsy. Clinical drug investigation. vol 41. issue 3. 2021-05-04. PMID:33559102. |
anecdotal reports addressing the successful seizure treatment of severe epilepsies with cannabidiol (cbd) have increased both public interest and academic research. |
2021-05-04 |
2023-08-13 |
Not clear |
| Ewa Galaj, Guo-Hua Bi, Hong-Ju Yang, Zheng-Xiong X. Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT Neuropharmacology. vol 167. 2021-04-23. PMID:31437433. |
cannabidiol (cbd) is a u.s. fda-approved cannabinoid for the treatment of epilepsy and recently was reported to have therapeutic potential for other disorders. |
2021-04-23 |
2023-08-13 |
rat |
| Tyler E Gaston, Steve B Ampah, E Martina Bebin, Leslie P Grayson, Gary R Cutter, Kathleen Hernando, Jerzy P Szaflarsk. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. Epilepsy & behavior : E&B. vol 117. 2021-04-20. PMID:33667843. |
long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. |
2021-04-20 |
2023-08-13 |
Not clear |
| Tyler E Gaston, Steve B Ampah, E Martina Bebin, Leslie P Grayson, Gary R Cutter, Kathleen Hernando, Jerzy P Szaflarsk. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. Epilepsy & behavior : E&B. vol 117. 2021-04-20. PMID:33667843. |
to evaluate the safety, efficacy, and tolerability of highly purified cannabidiol (cbd) for the treatment of seizures in children and adults with treatment-resistant epilepsy (tre) in an open-label, expanded access program (eap). |
2021-04-20 |
2023-08-13 |
Not clear |
| Birgitta Metternich, Kathrin Wagner, Maximilian J Geiger, Martin Hirsch, Andreas Schulze-Bonhage, Kerstin A Klot. Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy. Epilepsy & behavior : E&B. vol 114. issue Pt A. 2021-04-19. PMID:33246899. |
cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy. |
2021-04-19 |
2023-08-13 |
Not clear |
| Birgitta Metternich, Kathrin Wagner, Maximilian J Geiger, Martin Hirsch, Andreas Schulze-Bonhage, Kerstin A Klot. Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy. Epilepsy & behavior : E&B. vol 114. issue Pt A. 2021-04-19. PMID:33246899. |
therapeutic use of cannabidiol (cbd) in intractable epilepsies has increased considerably over the last ten years. |
2021-04-19 |
2023-08-13 |
Not clear |
| Rodolphe Nenert, Jane B Allendorfer, E Martina Bebin, Tyler E Gaston, Leslie E Grayson, James T Houston, Jerzy P Szaflarsk. Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy. Epilepsy & behavior : E&B. vol 112. 2021-04-14. PMID:32745959. |
cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy. |
2021-04-14 |
2023-08-13 |
Not clear |
| Tyler E Gaston, Jane B Allendorfer, Sangeeta Nair, E Martina Bebin, Leslie P Grayson, Roy C Martin, Jerzy P Szaflarsk. Effects of highly purified cannabidiol (CBD) on fMRI of working memory in treatment-resistant epilepsy. Epilepsy & behavior : E&B. vol 112. 2021-04-14. PMID:32871501. |
effects of highly purified cannabidiol (cbd) on fmri of working memory in treatment-resistant epilepsy. |
2021-04-14 |
2023-08-13 |
Not clear |
| Tyler E Gaston, Jane B Allendorfer, Sangeeta Nair, E Martina Bebin, Leslie P Grayson, Roy C Martin, Jerzy P Szaflarsk. Effects of highly purified cannabidiol (CBD) on fMRI of working memory in treatment-resistant epilepsy. Epilepsy & behavior : E&B. vol 112. 2021-04-14. PMID:32871501. |
we aimed to determine changes in working memory and functional connectivity via functional magnetic resonance imaging (fmri)-modified sternberg task after treatment with highly purified cannabidiol (cbd, epidiolex®; 100 mg/ml) in patients with treatment-resistant epilepsy (tre). |
2021-04-14 |
2023-08-13 |
Not clear |
| Yong D Park, Daniel F Linder, Jamie Pope, J Robert Flamini, Katherine Moretz, Michael P Diamond, Sarah A Lon. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program. Epilepsy & behavior : E&B. vol 112. 2021-04-14. PMID:33181893. |
long-term efficacy and safety of cannabidiol (cbd) in children with treatment-resistant epilepsy: results from a state-based expanded access program. |
2021-04-14 |
2023-08-13 |
Not clear |
| Yong D Park, Daniel F Linder, Jamie Pope, J Robert Flamini, Katherine Moretz, Michael P Diamond, Sarah A Lon. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program. Epilepsy & behavior : E&B. vol 112. 2021-04-14. PMID:33181893. |
this study provided children with treatment-resistant epilepsy (tre) access to plant-derived highly purified cannabidiol (cbd; epidiolex® in the us; epidyolex® in the eu; 100 mg/ml oral solution). |
2021-04-14 |
2023-08-13 |
Not clear |
| Claudia Taborda Gómez, Fabiana Lairion, Marisa Repetto, Miren Ettcheto, Amalia Merelli, Alberto Lazarowski, Jerónimo Auzmend. Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment. Pharmaceuticals (Basel, Switzerland). vol 14. issue 3. 2021-04-13. PMID:33807975. |
cannabidiol (cbd), a lipophilic cannabinoid compound without psychoactive effects, has emerged as adjuvant of anti-epileptic drugs (aeds) in the treatment of refractory epilepsy (re), decreasing the severity and/or frequency of seizures. |
2021-04-13 |
2023-08-13 |
Not clear |
| Yesim Coskun, Canan Yildiri. A 3-year-old child with multi-drug resistant epilepsy responding to pharmacological and nonpharmacological treatments. The International journal of neuroscience. 2021-04-12. PMID:33843424. |
herein, we report a 3-year-old child with multi-drug resistant epilepsy caused by perinatal asphyxia whose seizures were reduced by 90% after the introduction of ketogenic diet, vagal nerve stimulation (vns) aspiresr (sr-seizure response) and oral cannabidiol. |
2021-04-12 |
2023-08-13 |
Not clear |
| b' Kristijonas Puteikis, R\\xc5\\xabta Mameni\\xc5\\xa1kien\\xc4\\x9. Use of cannabis and its products among patients in a tertiary epilepsy center: A cross-sectional survey. Epilepsy & behavior : E&B. vol 111. 2021-03-23. PMID:32580133.' |
use of cannabis and its products among patients in a tertiary epilepsy center: a cross-sectional survey. |
2021-03-23 |
2023-08-13 |
Not clear |
| b' Kristijonas Puteikis, R\\xc5\\xabta Mameni\\xc5\\xa1kien\\xc4\\x9. Use of cannabis and its products among patients in a tertiary epilepsy center: A cross-sectional survey. Epilepsy & behavior : E&B. vol 111. 2021-03-23. PMID:32580133.' |
the purpose of this study was to evaluate whether the topic of using cannabis as a treatment option for epilepsy is relevant among adult patients with the disorder and assess the possible determinant attitudes for having a history of cannabis consumption or being inclined to try it for medical purposes. |
2021-03-23 |
2023-08-13 |
Not clear |
| Manuela Contin, Susan Mohamed, Margherita Santucci, Monica Anna Maria Lodi, Emilio Russo, Oriano Mecarelli, Cbd Lice Italy Study Grou. Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program. Frontiers in pharmacology. vol 12. 2021-03-23. PMID:33746760. |
cannabidiol in pharmacoresistant epilepsy: clinical pharmacokinetic data from an expanded access program. |
2021-03-23 |
2023-08-13 |
Not clear |
| Jesse Elliott, Deirdre DeJean, Beth K Potter, Doug Coyle, Tammy Clifford, Bláthnaid McCoy, George A Well. Barriers in accessing medical cannabis for children with drug-resistant epilepsy in Canada: A qualitative study. Epilepsy & behavior : E&B. vol 111. 2021-03-22. PMID:32570201. |
barriers in accessing medical cannabis for children with drug-resistant epilepsy in canada: a qualitative study. |
2021-03-22 |
2023-08-13 |
Not clear |
| Jesse Elliott, Deirdre DeJean, Beth K Potter, Doug Coyle, Tammy Clifford, Bláthnaid McCoy, George A Well. Barriers in accessing medical cannabis for children with drug-resistant epilepsy in Canada: A qualitative study. Epilepsy & behavior : E&B. vol 111. 2021-03-22. PMID:32570201. |
the use of medical cannabis to treat drug-resistant epilepsy in children is increasing; however, there has been limited study of the experiences of parents with the current system of accessing medical cannabis for their children. |
2021-03-22 |
2023-08-13 |
Not clear |